Complement Activation Selectively Potentiates the Pathogenicity of the IgG2b and IgG3 Isotypes of a High Affinity Anti-Erythrocyte Autoantibody by da Silveira, Samareh Azeredo et al.
 
J. Exp. Med. 
 

 
 The Rockefeller University Press • 0022-1007/2002/03/665/08 $5.00
Volume 195, Number 6, March 18, 2002 665–672
http://www.jem.org/cgi/content/full/195/6/665
 
665
 
Complement Activation Selectively Potentiates the 
Pathogenicity of the IgG2b and IgG3 Isotypes of a
High Afﬁnity Anti-Erythrocyte Autoantibody
 
Samareh Azeredo da Silveira,
 
1
 
 Shuichi Kikuchi,
 
1
 
Liliane Fossati-Jimack,
 
2
 
 Thomas Moll,
 
1
 
 Takashi Saito,
 
3
 
 J. Sjef Verbeek,
 
4
 
Marina Botto,
 
2
 
 Mark J. Walport,
 
2
 
 Michael Carroll,
 
5
 
 and Shozo Izui
 
1
 
1
 
Department of Pathology, University of Geneva, 1211 Geneva 4, Switzerland
 
2
 
Rheumatology Section, Hammersmith Campus, Imperial College School of Medicine, London
W12 0NN, United Kingdom
 
3
 
Department of Molecular Genetics, Chiba University Graduate School of Medicine, Chiba 260, Japan
 
4
 
Department of Human and Clinical Genetics, Leiden University Medical Center, 2300 RA
Leiden, Netherlands
 
5
 
Center for Blood Research and Department of Pathology, Harvard Medical School, Boston, MA 02115
 
Abstract
 
By generating four IgG isotype-switch variants of the high affinity 34–3C anti-erythrocyte au-
toantibody, and comparing them to the IgG variants of the low affinity 4C8 anti-erythrocyte
autoantibody that we have previously studied, we evaluated in this study how high affinity
binding to erythrocytes influences the pathogenicity of each IgG isotype in relation to the re-
spective contributions of Fc
 
 
 
 receptor (Fc
 
 
 
R) and complement. The 34–3C autoantibody op-
sonizing extensively circulating erythrocytes efficiently activated complement in vivo (IgG2a 
 
 
 
IgG2b 
 
  
 
IgG3), except for the IgG1 isotype, while the 4C8 IgG autoantibody failed to activate
complement. The pathogenicity of the 34–3C autoantibody of IgG2b and IgG3 isotypes was
dramatically higher (
 
 
 
200-fold) than that of the corresponding isotypes of the 4C8 antibody.
This enhanced activity was highly (IgG2b) or totally (IgG3) dependent on complement. In
contrast, erythrocyte-binding affinities only played a minor role in in vivo hemolytic activities
of the IgG1 and IgG2a isotypes of 34–3C and 4C8 antibodies, where complement was not or
only partially involved, respectively. The remarkably different capacities of four different IgG
 
isotypes of low and high affinity anti-erythrocyte autoantibodies to activate Fc
 
 
 
R-bearing
effector cells and complement in vivo demonstrate the role of autoantibody affinity matura-
tion and of IgG isotype switching in autoantibody-mediated pathology.
 
Key words: autoimmune hemolytic anemia • complement receptor • Fc receptor • IgG isotype • 
phagocytosis
 
Introduction
 
Autoantibodies are the essential factors for particular clini-
cal manifestations associated with a number of autoimmune
diseases. The pathogenic potential of autoantibodies is
likely to be determined by the combined action of the self-
antigen binding properties (specificity and affinity) of the
Fab region and the effector functions associated with the Fc
region of the different Ig isotypes. Therefore, it is conceiv-
able that a change of Ig isotype may result in a remarkable
change of the autoantibody’s pathogenic potential, because
Ig class switching can alter Fc-dependent effector functions
and can be accompanied by concomitant changes in au-
toantibody affinity. To address this question, we have re-
cently analyzed the pathogenic activity of four different
IgG switch variants derived from a murine anti-RBC mono-
clonal autoantibody, 4C8, originally established from au-
toimmune-prone NZB mice (1, 2). To our surprise, de-
spite its very poor RBC-binding activity, the IgG2a isotype
of the low affinity 4C8 mAb was highly pathogenic and ca-
pable of inducing anemia at a dose comparable to that of a
high affinity 34–3C IgG2a anti-RBC mAb. This high
pathogenicity was apparently due to the capacity of the
IgG2a isotype to interact very efficiently with the IgG Fc
receptor (Fc
 
 
 
R) involved in erythrophagocytosis, consis-
tent with a poor pathogenicity of the three other IgG iso-
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types (IgG1, IgG2b, and IgG3) of the 4C8 mAb having a
limited interaction with Fc
 
 
 
R. However, it has not been
explored whether high affinity anti-RBC autoantibodies of
IgG1, IgG2b, and IgG3 isotypes could become more
pathogenic as a result of a markedly increased RBC-bind-
ing and thereby enhanced interaction with Fc
 
 
 
R and/or
activation of complement.
Among the various effector functions mediated by the Ig
heavy-chain constant regions, Fc
 
 
 
R-mediated erythro-
phagocytosis has been recognized as the major pathogenic
mechanism responsible for autoimmune hemolytic anemia
in mice (2–5). Murine phagocytic effector cells express two
different classes of phagocytic Fc
 
 
 
R, high affinity Fc
 
 
 
RI,
and low affinity Fc
 
 
 
RIII (for a review, see reference 6).
These are hetero-oligomeric complexes, in which the re-
spective ligand-binding 
 
 
 
-chains are associated with the
common 
 
 
 
-chain (FcR
 
 
 
). FcR
 
 
 
 is required for the assembly
of both Fc
 
 
 
RI and Fc
 
 
 
RIII and for the triggering of their
various effector functions, including phagocytosis (7). Our
recent analysis by the use of different strains of Fc
 
 
 
R-defi-
cient mice revealed that the capacity of each IgG isotype to
interact with the low affinity Fc
 
 
 
RIII is the critical factor
determining the pathogenic potency of individual IgG iso-
types of the 4C8 anti-RBC mAb (1, 2), as the high affinity
Fc
 
 
 
RI apparently plays a relatively limited role, probably be-
cause of the competition by circulating monomeric IgG2a.
In contrast, it has been suggested that complement acti-
vation plays a minimal role in the development of anemia
induced by anti-RBC antibodies (3, 4, 8). However, the
interpretation of these results was still tentative, as murine
IgG2a, IgG2b, and IgG3 isotypes (but not IgG1) efficiently
activate complement (9, 10). The lack of the involvement
of complement in anemia induced by the low affinity 4C8
IgG switch variants could be due to a limited opsonization
of RBC in mice injected with this mAb (1, 2). Earlier stud-
ies in complement-deficient guinea pigs suggested the syn-
ergistic cooperation of Fc
 
 
 
R and CRs expressed on
Kupffer cells in erythrophagocytosis of RBCs sensitized
with polyclonal rabbit anti-RBC antibodies (11). Thus, the
pathogenicity of high affinity anti-RBC autoantibodies of
IgG2b and IgG3 isotypes, which poorly interact with
Fc
 
 
 
R, could be promoted as a result of complement acti-
vation, either by acting synergistically with Fc
 
 
 
R or by
triggering CR-dependent erythrophagocytosis.
We have generated IgG class-switch variants (IgG1,
IgG2b, and IgG3) of the high affinity 34–3C IgG2a anti-
RBC mAb derived from NZB mice (3) in order to better
define the role of autoantibody binding affinities in relation
to Fc-associated effector functions in the development of
autoimmune hemolytic anemia. The level of in vivo op-
sonization of circulating RBCs induced by the high affinity
34–3C mAb was remarkably enhanced, compared with the
low affinity 4C8 anti-RBC IgG variants having 
 
 
 
1,000
times weaker RBC-binding activity (1). Therefore, by as-
sessing the pathogenic effect of the 34–3C IgG variants in
mice deficient in Fc
 
 
 
R and/or C3, we should be able to
study how high affinity binding to RBCs modulates the
pathogenic potential of each IgG isotype, and whether the
level of RBC opsonization in vivo could influence the ex-
tent of complement activation and Fc
 
 
 
R interaction. We
show in this study that the pathogenicity of the high affin-
ity 34–3C anti-RBC mAb is markedly enhanced, com-
pared with that of the low affinity 4C8 mAb, but in an IgG
isotype-dependent manner. Remarkable and selective en-
hancement of the pathogenicity of the IgG2b and IgG3
isotypes (
 
 
 
200-fold increases) was associated with a marked
activation of complement, as a result of extensive opsoniza-
tion of circulating RBCs. In contrast, for the IgG1 and
IgG2a isotypes, high affinity binding exhibited only a min-
imal effect on their hemolytic activities in vivo, which
were poorly dependent on complement activation.
 
Materials and Methods
 
Mice.
 
BALB/c mice were purchased from Gl. Bomholtgard
Ltd. FcR
 
 
 
-deficient (FcR
 
 
 
 
 
/
 
 
 
) mice (lacking functional expres-
sion of both Fc
 
 
 
RI and Fc
 
 
 
RIII) with a pure C57BL/6 (B6)
background, and their corresponding wild-type (WT)
 
*
 
 litter-
mates were developed as described previously (12). C1q- and C3-
deficient mice were backcrossed for 10 and 5 generations with B6
mice, respectively (13, 14). FcR
 
 
 
 and C3 double-deficient mice
(FcR
 
 
 
/C3
 
 
 
/
 
 
 
) were obtained from intercross between FcR
 
 
 
 
 
/
 
 
 
and C3
 
 
 
/
 
 
 
 B6 mice. Mice deficient in C3 were identified by the
absence of serum C3, as determined by ELISA, and the FcR
 
 
 
 
 
/
 
 
 
genotype was determined by PCR analysis using a combination
of the following sets of primers: WT-specific sense primer (5
 
 
 
-
CCAACGCTATGTCCTGATAG-3
 
 
 
), mutant-specific sense
primer (5
 
 
 
-TGCTGTCCTGTTTTTGTATGG-3
 
 
 
), and com-
mon antisense primer (5
 
 
 
-GCTGCCTTTCGGACCTGGAT-
3
 
 
 
). 
 
 
 
MT B6 mice deficient in B cells (15) were obtained from
B&K Universal.
 
DNA Constructions.
 
The VDJH34–3C-C
 
 
 
1, -C
 
 
 
2b, and
-C
 
 
 
3 plasmids containing the complete 34–3C IgG heavy-chain
gene of the respective IgG subclass were constructed using the
following DNA fragments: the rearranged VDJ (variable-diver-
sity-joining) region isolated from cDNA encoding the variable
region of the heavy chain of the 34–3C mAb, the promoter re-
gion isolated from pSV-V
 
 
 
1 (16), the heavy-chain enhancer re-
gion isolated from pSVE2-neo (17) and the C
 
 
 
1, C
 
 
 
2b, or C
 
 
 
3
region derived from the respective genomic clones, pEVHC
 
 
 
1
(17), pIgH22 (18), and pJW7 (19).
 
mAb.
 
The hybridoma secreting the 34–3C IgG2a high affin-
ity anti-RBC monoclonal autoantibody was derived from unma-
nipulated NZB mice (3). The 34–3C IgG1, IgG2b, and IgG3
class-switch variants were obtained by transfecting 34–3C heavy-
chain-loss mutant cells by electroporation with the respective
VDJH34–3C-C
 
 
 
 plasmids together with a pSVE2-neo plasmid
containing the neomycin-resistant gene, as described previously
(1). IgG mAb were purified from culture supernatants by protein
G column chromatography. The purity of IgG was 
 
 
 
90% as doc-
umented by SDS/PAGE. The 34–3C IgG class-switch variants
exhibited comparable mouse RBC-binding activity in vitro, as
assessed by a flow cytometric analysis (1). The generation of IgG
switch variants of the 4C8 low affinity anti-RBC mAb was de-
scribed previously (1, 2).
 
Detection of C3 in Sera and of Opsonized RBCs in the Circulating
Blood.
 
The presence or absence of C3 in sera from mice were
determined by ELISA. Briefly, IgG goat anti–mouse C3 antibod-
 
*
 
Abbreviations used in this paper:
 
 Ht, hematocrit; WT, wild-type. 
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ies (Capell Laboratories) were used for coating microtiter plates,
and incubated overnight at 4
 
 
 
C with serum samples at a dilution
of 1/1,000. Then, the assay was developed with alkaline phos-
phatase-labeled goat anti–mouse C3 conjugates. The presence of
opsonized RBCs in mice injected with 34–3C or 4C8 anti-RBC
mAb was detected by a similar flow cytometric assay, using bio-
tinylated goat anti–mouse C3 or rat anti–mouse 
 
k
 
 chain mAb
(H139.52.1.5), followed by PE-conjugated streptavidin, as de-
scribed (1). The specificity of the assay for C3 opsonization was
confirmed by the absence of staining on circulating RBCs in
C3
 
 
 
/
 
 
 
 mice.
 
Experimental Autoimmune Hemolytic Anemia.
 
Autoimmune
hemolytic anemia was induced by a single intraperitoneal injec-
tion of purified anti-RBC mAb into two to three mo-old mice.
Blood samples were collected into heparinized microhematocrit
tubes every 2 d after the injection, and hematocrits (Hts) were di-
rectly determined after centrifugation, as described previously (2).
The injection of mAb was controlled 24 h later by assessing the
level of antibody opsonization of circulating RBCs by a flow cy-
tometric analysis using biotinylated rat anti–mouse 
 
k
 
 chain mAb.
Livers were obtained 8 d after injection of mAb, processed for
histological examination, and stained with hematoxylin and
eosin. The extent of in vivo RBC destruction by Kupffer cell-
mediated phagocytosis was determined by Perls iron staining.
 
Statistical Analysis.
 
Statistical analysis was performed with the
Wilcoxon two-sample test. Probability values 
 
 
 
5% were consid-
ered significant.
 
Results
 
Efficient Activation of Complement by the High Affinity 34–
3C IgG Class-switch Variants, but Not by the Low Affinity
4C8 IgG Variants.
 
To assess the ability of individual IgG
isotypes of the 34–3C anti-RBC mAb to activate comple-
ment in vivo, we analyzed by flow cytometry the extent of
C3 deposition on circulating RBCs 24 h after a single intra-
peritoneal injection of 50 or 200 
 
 
 
g of purified mAb into
BALB/c mice. The highest and comparable levels of C3
opsonization were observed in mice injected with the
IgG2a and IgG2b isotypes; the IgG3 isotype was less effi-
cient (Fig. 1). As expected, no significant C3 opsonization
was observed in mice receiving the IgG1 isotype, which is
 
known not to activate complement efficiently (9, 10). As it
has been claimed that murine IgG3 isotype failed to activate
the classical pathway of complement (20), the levels of C3
opsonization were evaluated in C1q-deficient B6 mice.
When these mice were injected with 200 
 
 
 
g of the 34–3C
IgG3 variant, C3-opsonized RBCs were no longer detect-
able in the blood (Fig. 1), indicating the activation of the
classical complement pathway after the binding of the 34–
3C IgG3 mAb to RBCs. In contrast, the injection of the
low affinity 4C8 IgG variants of any isotype failed to induce
a significant C3 opsonization on circulating RBCs (Fig. 1).
 
Markedly Enhanced Pathogenicity of IgG2b and IgG3, but
not IgG1 and IgG2a Isotypes of the High Affinity 34–3C Anti-
RBC mAb, Compared with the Low Affinity 4C8 IgG Vari-
ants.
 
The pathogenic activity of individual IgG isotypes of
the 34–3C mAb was analyzed by a single intraperitoneal in-
jection of 200 
 
 
 
g of purified mAb into BALB/c mice. The
IgG2a and IgG2b isotypes of the 34–3C mAb induced the
most severe form of anemia (a decrease in mean Ht values to
10–12% at day 4), the IgG3 variant a mild anemia (average
Ht of 30%), and the IgG1 variant was unable to significantly
decrease Ht levels (Fig. 2). Notably, the extent of opsoniza-
tion of circulating RBCs 24 h after mAb injection was com-
parable in mice treated with different IgG variants, as re-
vealed by rat anti–mouse 
 
k
 
 chain mAb (data not shown).
To compare more quantitatively the pathogenic activity
of individual IgG isotypes of the 34–3C mAb, various
amounts of mAb were intraperitoneally injected into
BALB/c mice and the quantities of mAb required to in-
duce anemia (decreasing Ht values to 
 
 
 
40%) were esti-
mated. Mild anemia was induced by the injection of 25 
 
 
 
g
of the 34–3C IgG2a and IgG2b mAb, while 100 
 
 
 
g of the
IgG3 isotype and 500 
 
 
 
g of the IgG1 isotype were re-
quired to provoke a drop of Ht values below 40% (Table
I). Thus, the pathogenic potency of the 34–3C IgG2a and
IgG2b isotypes was approximately 4- and 20-fold higher
than that of the IgG3 and IgG1 isotypes, respectively. His-
tological examinations showed that the extent of eryth-
rophagocytosis, documented by iron deposits in hepatic
Figure 1. Flow cytometric analysis of comple-
ment activation in vivo by the 34–3C and 4C8 IgG
class-switch variants. Mouse RBCs were obtained
24 h after an intraperitoneal injection of 50 or 200
 g of 34–3C or 4C8 IgG variants into mice, and
then stained with biotinylated goat anti–mouse C3
antibodies, followed by PE-conjugated streptavidin.
Results obtained with 50  g (thick lines) and 200
 g (thin lines) of the 34–3C IgG2a, IgG2b, and
IgG3 variants in BALB/c mice, 200  g of the 34–
3C IgG3 variant in C1q /  mice, and 200  g of
the 34–3C IgG1 or 4C8 IgG2a variant in BALB/c
mice are shown. Shaded areas indicate the back-
ground staining with PE-conjugated streptavidin. 
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Kupffer cells, correlated in all these cases with the level of
anemia (data not shown).
When the pathogenic activity of the high affinity 34–3C
IgG variants was compared with that of the low affinity
4C8 IgG variants (2), the ability to induce mild anemia was
dramatically enhanced (200-fold and even more) in the 34–
3C IgG2b and IgG3 isotypes (Table I). In contrast, the
minimal amount of the IgG1 and IgG2a isotypes required
for the induction of mild anemia was almost comparable
between the 34–3C and 4C8 mAb. However, for the in-
duction of a severe form of anemia (causing a 50% decrease
in Ht values), 10 times lesser amounts of the 34–3C IgG2a
mAb (100 
 
 
 
g) were sufficient, compared with the 4C8
IgG2a mAb (1 mg), indicating that the high affinity 34–3C
IgG2a mAb became more pathogenic at higher doses than
the low affinity 4C8 IgG2a mAb.
 
Major Role of Fc
 
 
 
R and Secondary Role of Complement in
the Development of Anemia Induced by 34–3C IgG2a Anti-
RBC mAb.
 
As the 34–3C IgG2a mAb efficiently acti-
vated complement in vivo, we reevaluated the respective
contributions of Fc
 
 
 
R and complement to the anemia in-
duced by two different doses (50 and 200 
 
 
 
g) of the 34–3C
IgG2a mAb in B6 mice deficient in FcR
 
 
 
 (i.e. lacking
functional expression of both phagocytic Fc
 
 
 
RI and Fc-
 
 
 
RIII) and/or C3. The development of anemia occurring
in WT mice injected with 50 
 
 
 
g of the 34–3C IgG2a mAb
was almost completely prevented in FcR
 
 
 
 
 
/
 
 
 
 mice (
 
P
 
 
 
 
 
0.01), while no significant protection was observed in C3
 
 
 
/
 
 
 
mice (
 
P
 
 
 
 
 
 0.05; Fig. 3 and Table II). Histological analysis
still revealed the presence of substantial iron deposits in
Kupffer cells in FcR
 
 
 
 
 
/
 
 
 
 mice receiving the 34–3C IgG2a
mAb. However, such deposits were no longer detectable in
34–3C IgG2a mAb-injected FcR
 
 
 
/C3
 
 
 
/
 
 
 
 mice. In con-
trast, the level of protection from anemia provoked by the
injection of 200 
 
 
 
g mAb was only moderate in FcR
 
 
 
 
 
/
 
 
 
mice, while a lower but significant level of protection was
observed in C3
 
 
 
/
 
 
 
 mice (
 
P
 
 
 
 
 
 0.005; Fig. 3 and Table II).
Notably, the development of anemia was completely pre-
vented in FcR
 
 
 
/C3
 
 
 
/
 
 
 
 mice injected with this high dose
of the 34–3C IgG2a mAb (
 
P
 
 
 
  
 
0.01). These data indicated
a minor but still significant contribution of CR-mediated
erythrophagocytosis to the development of the severe form
of anemia induced by a high dose (200 
 
 
 
g) of the 34–3C
IgG2a mAb.
 
Comparable Contributions of Fc
 
 
 
R and Complement to the
Development of Anemia Induced by 34–3C IgG2b Anti-RBC
mAb.
 
We similarly evaluated the respective roles of Fc
 
 
 
R
and complement in the development of anemia induced by
the 34–3C IgG2b mAb. This antibody is able to activate
complement as strongly as the IgG2a isotype, but interacts
less efficiently with Fc
 
 
 
R (2). The development of anemia
occurring in WT B6 mice injected with 50 
 
 
 
g of the 34–
3C IgG2b mAb was completely prevented in FcR
 
 
 
 
 
/
 
 
 
 B6
mice (
 
P
 
 
 
 
 
 0.005; Fig. 4 and Table II). Histological analysis
confirmed the absence of erythrophagocytosis, as docu-
mented by the lack of iron deposits in Kupffer cells. How-
ever, unlike after injection of the 34–3C IgG2a mAb, the
development of anemia was also markedly prevented in
Figure 2. Development of anemia induced by the 34–3C IgG class-
switch variants in mice. BALB/c mice were injected intraperitoneally with
200  g of purified 34–3C IgG variants (IgG1,  ; IgG2a,  ; IgG2b,  ;
IgG3,  ) on day 0. Results are expressed as mean Ht values of five mice.
 
Table I.
 
Estimation of Quantities of the High Affinity 34–3C and 
Low Affinity 4C8 IgG Class-switch Variants Required for Inducing 
Mild and Severe Anemia
 
34-3C mAb 4C8 mAb
Isotype
Mild
anemia
 
a
 
Severe
anemia
 
b
 
Mild
anemia
 
a
 
Severe
anemia
 
b
 
IgG1 500 
 
 
 
gN D
 
c
 
1 mg ND
IgG2a 25 
 
 
 
g 100 
 
 
 
g 50 
 
 
 
g 1 mg
IgG2b 25 
 
 
 
g 100 
 
 
 
g
 
 
 
5 mg ND
IgG3 100 
 
 
 
g ND Not pathogenic
 
a
 
The quantity of the 34-3C and 4C8 IgG variants required for induc-
ing mild anemia (decreasing Ht values to 
 
 
 
40%) in BALB/c mice.
 
b
 
The quantity of the 34-3C and 4C8 IgG variants required for induc-
ing severe anemia (causing a 50% decrease in Ht values) in BALB/c
mice.
cNot done.
Figure 3. Development of anemia in WT, C3 / , FcR  / , or
FcR /C3 /  mice after the injection of the 34–3C IgG2a mAb. Ht val-
ues of individual mice measured 4 d after the intraperitoneal injection of
50 or 200  g of the mAb are shown.669 Azeredo da Silveira et al.
C3 /  mice (P   0.005), which exhibited only a limited
extent of erythrophagocytosis. At a highly pathogenic dose
(200  g) of the 34–3C IgG2b mAb, the development of
anemia was strongly, though not completely, inhibited in
both FcR  /  and C3 /  mice (P   0.005; Fig. 4 and Ta-
ble II). As in the case of the IgG2a isotype, FcR /C3 / 
mice were totally resistant to the pathogenic effect of 200
 g of the 34–3C IgG2b mAb (P   0.01), and did not
show any significant iron deposits in Kupffer cells.
Differential Role of Fc R and Complement in the Develop-
ment of Anemia Induced by 34–3C IgG1 and IgG3 Anti-RBC
mAb. Using high affinity 105–2H IgG1 and low affinity
4C8 IgG1 anti-RBC mAb derived from NZB mice, it has
been well established that Fc RIII is the sole Fc R medi-
ating IgG1-dependent phagocytosis in vivo (2, 5, 21). In
agreement with these prior observations, FcR  /  mice
were completely resistant to the pathogenic effect of the
34–3C IgG1 variant (P   0.01), and failed to show any
sign of erythrophagocytosis (Fig. 5 and Table II). Notably,
the development of anemia was not prevented in C3 / 
mice after the injection of the 34–3C IgG1 isotype.
Unlike the IgG1, IgG2a, and IgG2b isotypes of the 34–
3C mAb, FcR -deficient mice were not resistant at all to
the pathogenic effect of 200  g of the 34–3C IgG3 variant
(Fig. 5 and Table II). In contrast, the development of ane-
mia was completely prevented in C3 /  mice (P   0.01),
in which erythrophagocytosis by Kupffer cells was no
longer detectable.
A recent in vitro study has reported that polymeric IgG3
is capable of interacting with Fc RI (22). Thus, an only
limited usage of Fc RI in vivo for phagocytosis of 34–3C
IgG3-opsonized RBCs could be due to competition with
excess amounts of circulating monomeric IgG2a having a
high affinity interaction with Fc RI (23). If this were the
case, one could expect an enhancement of the pathogenic
effect of the 34–3C IgG3 mAb in Ig-deficient  MT B6
mice because of the absence of competition with IgG2a.
However, after injection of 50  g of the 34–3C IgG3
Table II. Pathogenic Activities of the 34–3C IgG Class-switch Variants in WT, C3 / , FcR  / , and FcR /C3 /  B6 Mice
Ht (%)a In vivo erythrophagocytosisb
Isotype Dose WT C3 /  FcR  /  FcR /C3 /  WT C3 /  FcR  /  FcR /C3 / 
IgG2a 50  g 25   3 28   4 39   1 46   2          
200  g 10   3 21   4 28   1 43   2       /        
IgG2b 50  g 28   2 38   3 44   1N D c  /       ND
200  g 12   3 36   3 36   1 45   2      /    /    
IgG1 500  g 37   1 38   2 46   2N D      ND
IgG3 200  g 30   3 40   1 30   3N D      ND
aHt values (mean of 4–5 mice   1SD) were determined 4 d after the intraperitoneal injection of purified 34–3C IgG variants (data from Figs. 3, 4,
and 5). Ht values before the injection of anti-RBC mAb in WT, C3 / , FcR  / , and FcR /C3 /  mice were in a range from 44–48%.
bThe extent of erythrophagocytosis by Kupffer cells in the liver is arbitrarily graded, in a blinded fashion, on the basis of the intensity of Perls iron
staining on liver sections.
cNot done.
Figure 4. Development of anemia in WT, C3 / , FcR  / , or
FcR /C3 /  mice after the injection of the 34–3C IgG2b variant. Ht
values of individual mice measured 4 d after the intraperitoneal injection
of 50 or 200  g of the mAb are shown.
Figure 5. Development of anemia in WT, C3 / , or FcR  /  mice
after the injection of 34–3C IgG1 or IgG3 variant. Ht values of individual
mice measured 4 d after the intraperitoneal injection of 500  g of 34–3C
IgG1 or 200  g of 34–3C IgG3 mAb are shown.670 Complement and Fc  Receptors in Autoimmune Hemolytic Anemia
mAb,  MT mice failed to show significant drops in Ht
values and increased sign of erythrophagocytosis, com-
pared with WT mice (mean Ht values of four mice 4 d
after the injection:  MT mice, 46.9   1.3%; WT mice,
45.5   0.5%).
Discussion
We have generated three IgG class-switch variants bear-
ing identical VH and Vk regions of a high affinity 34–3C
IgG2a anti-RBC autoantibody derived from lupus-prone
NZB mice, and determined how a high binding affinity to
circulating RBCs influenced the pathogenicity of individ-
ual IgG isotypes in relation to the respective contributions
of Fc R and complement. Strikingly, the pattern of the
IgG isotype-dependent pathogenicity of the 34–3C mAb
(IgG2a   IgG2b   IgG3   IgG1) was totally different
from that of the low affinity 4C8 mAb (IgG2a   IgG1  
IgG2b   IgG3) (2). The combined analysis in mice defi-
cient in FcR  or C3 revealed that this difference was pri-
marily due to a marked enhancement of the pathogenic ef-
fect of the IgG2b and IgG3 isotypes ( 200-fold increases)
as a result of complement activation, which not only trig-
gered CR-dependent erythrophagocytosis but also pro-
moted Fc R-mediated erythrophagocytosis through syner-
gistic cooperation with CR. In contrast, a high affinity
binding to RBCs barely augmented in vivo hemolytic ac-
tivities of the IgG1 and IgG2a isotypes, in which comple-
ment played no or only a minimal role. Our data thus de-
fine the role of autoantibody affinity maturation and IgG
isotype switching in relation to the activation of Fc R and
complement in vivo in the pathogenesis of autoimmune
hemolytic anemia.
The analysis of IgG switch variants of the high affinity
34–3C mAb has clarified the issue concerning the role of
complement in the development of autoimmune hemolytic
anemia (Table III). As already described previously (2, 4, 5),
Fc R-mediated erythrophagocytosis was the major mecha-
nism for the induction of anemia induced by the IgG2a iso-
type, which most efficiently interacts with both classes of
phagocytic Fc R, Fc RI, and Fc RIII (2). C3 deficiency
only minimally affected the development of mild anemia at
a low dose (50  g) of this isotype, despite its efficient acti-
vation of complement. This indicates that CR-mediated
erythrophagocytosis apparently requires an extensive op-
sonization of C3 fragments on RBCs. On the contrary, a
limited opsonization with IgG2a antibodies is sufficient to
trigger Fc R-dependent erythrophagocytosis, as observed
in mice injected with the low affinity 4C8 IgG2a mAb,
which very poorly opsonizes circulating RBCs (1). Nota-
bly, CR-dependent erythrophagocytosis significantly con-
tributed to the development of the severe form of anemia
induced by a high dose (200  g) of the 34–3C IgG2a mAb.
Thus, differential contribution of complement to the devel-
opment of anemia induced by low and high doses of the
high affinity 34–3C IgG2a mAb would explain why the
34–3C mAb became more pathogenic only at higher doses,
but not at lower doses, compared with the low affinity 4C8
mAb, which poorly activated complement in vivo. The lat-
ter observation also indicates that relatively high density of
IgG is required for efficient binding and activation of C1.
Thus, complement activation by the classical pathway could
be markedly influenced by antibody affinity, in addition to
the density and distribution of epitope, which is responsible
for creating an appropriate angle of the Fab arms of IgG re-
quired for C1 activation (24, 25).
In contrast to the IgG2a isotype, both complement and
Fc R contributed almost equally well to the development
of anemia induced by the IgG2b isotype (Table III). How-
ever, the role of complement is apparently different be-
tween anemia induced at low and high doses of this isotype.
The development of mild anemia provoked by a low dose
(50  g) was markedly prevented in C3 /  mice, but com-
pletely prevented in Fc R-deficient mice. This last obser-
vation suggests that Fc R is the sole receptor involved in
erythrophagocytosis, but that, because of a very weak affin-
ity of Fc R to the IgG2b isotype (2), moderately opsonized
RBCs require an additional involvement of complement to
trigger optimally Fc R-dependent phagocytosis. This in-
terpretation is consistent with previous reports suggesting a
synergistic cooperation of CR and Fc R for phagocytosis
in vivo and in vitro (11, 26, 27). However, this was no
longer the case for severe anemia after injection of a high
dose (200  g) of the IgG2b isotype, as anemia developed in
mice deficient in either Fc R or C3, but not in those defi-
cient in both Fc R and C3. It is possible that the extensive
opsonization resulting from the injection of this high dose
could not only overcome the low avidity interaction be-
tween Fc R and IgG2b isotype to provoke Fc R-medi-
ated phagocytosis, independently of complement activa-
tion, but also trigger CR-mediated erythrophagocytosis.
Our data thus indicate a critical role for the autoantibody
affinity in the pathogenic activity of the IgG2b isotype by
promoting IgG Fc-associated effector functions.
As expected from our previous studies (2, 5), the 34–3C
IgG1 isotype triggered erythrophagocytosis only by activat-
ing Fc R, but not complement (Table III). It is somehow
surprising to see that the pathogenic potential of the high
affinity 34–3C IgG1 mAb was poor and almost comparable
to that of the low affinity 4C8 IgG1 variant. This is likely
to result from the lack of complement activation, which is,
in contrast, partly responsible for the markedly enhanced
Table III. Pathogenic Activities of the 34–3C IgG Class-switch 
Variants and Respective Contributions of Fc R and Complement to 
the 34–3C IgG-induced Anemia
Isotype Pathogenicity Effector functions
IgG2a     Fc R   complement
IgG2b     Fc R and complement
IgG3    Complement
IgG1   Fc R671 Azeredo da Silveira et al.
pathogenicity of the IgG2b isotype of the high affinity 34–
3C mAb, as discussed above. Another important difference
is that the IgG1 isotype interacts only with Fc RIII (2, 5,
21), while the IgG2b isotype is apparently able to interact
not only with Fc RIII but also with another phagocytic
receptor, Fc RI (2). In this respect, we recently observed
that the development of anemia triggered by the 34–3C
IgG2b variant was significantly inhibited in Fc RI-defi-
cient mice as well as in Fc RIII-deficient mice (unpub-
lished data). Accordingly, RBCs highly opsonized with
34–3C IgG2b mAb could interact with three different re-
ceptors, Fc RI, Fc RIII, and CR, thereby potentiating
erythrophagocytosis through synergistic cooperation among
these three receptors.
In marked contrast to the three other IgG isotypes, the
development of anemia provoked by the high affinity 34–
3C IgG3 variant was totally dependent on complement ac-
tivation, and this isotype apparently fails to interact with
phagocytic Fc R (Table III). There has been a controversy
about the presence of any receptor for murine IgG3 iso-
type. Diamond and Yelton have proposed the presence of
an IgG3-specific phagocytic Fc R expressed on macro-
phages (28). This has also been supported by a recent study,
demonstrating the possible involvement of nonconven-
tional Fc R in the phagocytosis of IgG3-opsonized crypto-
cocci by peritoneal macrophages in vitro (29). In contrast,
using bone marrow–derived macrophages from Fc RI-
deficient mice, Fc RI has been claimed to be the sole re-
ceptor for the IgG3 isotype (22). The present results show-
ing that Kupffer cell–mediated phagocytosis of RBCs highly
opsonized with the 34–3C IgG3 mAb is not inhibited in
FcR -deficient mice, but completely abrogated in C3-defi-
cient mice strongly argue not only against any significant af-
finity of conventional Fc R to murine IgG3 isotype in
vivo, but also against the presence of a novel IgG3-specific
Fc R mediating phagocytosis. The absence of interaction of
34–3C IgG3-opsonized RBCs with Fc RI in vivo could be
explained by competition with circulating monomeric
IgG2a having a high affinity interaction with Fc RI (23).
However, the lack of enhanced erythrophagocytosis by
Kupffer cells in Ig-deficient  MT mice after injection of
the 34–3C IgG3 mAb argues against this hypothesis.
The use of four different anti-RBC IgG switch variants
of the high affinity 34–3C and the low affinity 4C8 mAb in
this and previous studies (2) has provided a unique oppor-
tunity to define the pathogenic potency of individual mu-
rine IgG isotypes in relation to autoantibody affinity and to
IgG Fc-dependent effector functions in the development of
autoimmune hemolytic anemia. Taken together, our stud-
ies have demonstrated the importance of the autoantigen-
binding affinity for the pathogenicity of certain IgG iso-
types (IgG2b and IgG3) by promoting the activation of
complement and/or Fc R-bearing effector cells. Studies
with an IgG2a anti-platelet monoclonal autoantibody have
shown a minimal role of complement in immune elimina-
tion of platelets (4, 8, 30); however, more extensive analy-
sis with other IgG isotypes of anti-platelet autoantibodies is
awaited to elucidate the potential role of complement
in immune thrombocytopenic purpura. Furthermore, it
should also be stressed that, in addition to the role of Fc R
in activation of inflammatory effector cells (12, 31, 32),
complement is apparently required for the full-blown ex-
pression of immune complex–mediated inflammatory reac-
tions in several experimental models including Arthus reac-
tion, immune complex alveolitis, and anti-glomerular
basement membrane nephritis (33–37). Thus, complement
is actively implicated in autoantibody- and immune com-
plex–triggered inflammatory cascades, in addition to its es-
sential role in innate immune responses (14, 38, 39). Given
the role of Fc R and complement in phagocytosis, cellular
cytotoxicity, and inflammatory reactions, further analysis of
autoantibody-triggered cellular and tissue injuries in rela-
tion to the respective roles of Fc R and complement
would help establish new strategies for the development of
therapeutic approaches in autoantibody- and immune
complex–mediated inflammatory disorders.
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